Date:8/17/2010

ses (49,156) (7,197) (66,842) (9,857) Operating income 25,809 3,779 27,916 4,116 Other income Interest income 2,454 359 2,357 348 Grant income 93 14 93 14 Net realized gain on available- for-sale securities 1,611 236 -- -- Others 1,681 246 881 130 Total other income 5,839 855 3,331 492 Income before income tax expense 31,648 4,634 31,247 4,608 Income tax expense (4,670) (684) (5,723) (844) Net income 26,978 3,950 25,524 3,764 Net income per share: Basic and diluted 0.18 0.03 0.17 0.02 Basic weighted average number of shares outstanding 150,586,455 150,586,455 150,849,065 150,849,065 Diluted weighted average number of shares outstanding 150,719,313 150,719,313 154,426,639 154,426,639 Net income per ADS: Basic 1.25 0.18 1.18 0.17 Diluted 1.25 0.18 1.16 0.17 Basic weighted average number of ADSs outstanding 21,512,351 21,512,351 21,549,866 21,549,866 Diluted weighted average number of ADSs outstanding 21,531,330 21,512,330 22,060,948 22,060,948 3SBio Inc. Unaudited quarterly consolidated statements of income (expressed in thousands, except per share , per ADS and other share and ADS data) For the Six For the Six Months Ended Months Ended June 30, 2009 June 30, 2010 RMB US$ RMB US$ (unaudited)(unaudited)(unaudited)(unaudited) Net Revenues: EPIAO 93,991 13,761 120,009 17,697 TPIAO 40,927 5,992 62,120 9,160 Intefen 2,555 374 2,573 379 Inleusin 693 101 1,033 152 Iron sulcrose 4,997 732 8,577 1,265 Export 6,851 1,003 5,982 882 Others 67 10 1,574 232 Total net revenues 150,081 21,973 201,868 29,767 Cost of revenues (12,517) (1,833) (18,594) (2,742) Gross profit 137,564 20,140 183,274 27,025 Operating expenses Research and development costs (6,709) (982) (10,423) (1,537) Sales, marketing and distribution expenses (69,191) (10,130) (90,136) (13,291) General and administrative expenses (15,751) (2,306) (26,573) (3,918) Total operating expenses (91,651) (13,418) (127,132) (18,746) Operating income 45,913 6,722 56,142 8,279 Other income /(expenses), net Interest income 6,526 955
'/>"/>

SOURCE 3SBio Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
Related biology technology :

1. 3SBio Inc. Announces Second Quarter 2008 Results
2. 3SBio Inc. to Hold Annual General Meeting
3. 3SBio Inc. to Present at the Morgan Stanley Global Healthcare Unplugged Conference
4. 3SBio Inc. Announces Results of Annual General Meeting
5. 3SBio Inc. to Present at the UBS Global Life Sciences Conference
6. 3SBio Inc. Files for SFDA Approval of High-dose (36,000 IU) EPIAO
7. 3SBio Inc. Schedules 2008 Third Quarter Earnings Release on Monday, November 10, 2008
8. 3SBio Inc. Announces Preliminary Third Quarter 2008 Results
9. 3SBio Inc. Files for SFDA Approval of NuLeusin
10. 3SBio Inc. Announces Third Quarter 2008 Results
11. 3SBio Inc. to Present at the Piper Jaffray 20th Annual Health Care Conference